Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Vor Biopharma Inc.NASDAQ: VOR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $219.59M (cash outflow) rose 575.9% year over year, behind the +644.6% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +96.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$67.36M (-90.3%) for the fiscal year ending Dec 2026, a slowdown from the +495.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$219.59M-112.7% QoQ
- Last fiscal yearDec 2025
- -$695.98M+495.3% YoY
- LTMMar 2026
- -$883.08M+644.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (695.98M) USD
- Year-over-year change
- -495.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (695.98M) | -495.3% |
| FY2024 | 2024-12-31 | (116.91M) | +0.8% |
| FY2023 | 2023-12-31 | (117.86M) | -28.0% |
| FY2022 | 2022-12-31 | (92.09M) | -33.7% |
| FY2021 | 2021-12-31 | (68.9M) | — |
Net Income vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 net income of $883.08M is the largest of the 10 companies compared; the peer median is $209.38M.
- Its year-over-year change of +644.6% is the highest of 10, against a peer median of -6.6%.
- Over three fiscal years its annual growth of +96.2% compares with a peer median of -3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $883.08M | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $500.92M | -4.8% | +3.1% | 757.9% | |
| LTM Sep 2026 | $456.14M | -6.6% | -3.6% | 1812.1% | |
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
| LTM Mar 2026 | $241.99M | +16.0% | -3.2% | — | |
| LTM Mar 2026 | $209.38M | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $129.91M | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $108.95M | -56.6% | -10.1% | 281.6% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $99.93M | -10.2% | -2.9% | — | |
| Peer median (excluding VOR) | $209.38M | -6.6% | -3.2% | 757.9% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Depreciation & Amortization | 1.43M | 2.53M | 3.49M | 3.53M | 2.89M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.32M | 10.7M | 13.36M | 9.85M | 18.91M |
| Change in Working Capital | (9.19M) | (12.69M) | 650K | 5K | 10.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 405K | 0 | 2.85M | 2.24M | 0 |
| Other Working Capital | (9.59M) | (12.69M) | (2.2M) | (2.24M) | 10.21M |
| Other Non-Cash Items | 3.19M | 6.42M | 67K | 3.87M | 521.26M |
| Operating Cash Flow | (69.14M) | (85.14M) | (100.29M) | (99.66M) | (142.71M) |
| Capital Expenditures | (3.89M) | (8.46M) | (1.07M) | (229K) | (941K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (87.76M) | (123.19M) | (74.92M) | (9.91M) | (53.66M) |
| Sales of Investments | 0 | 37.56M | 147M | 107M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 799K |
| Investing Cash Flow | (91.65M) | (94.09M) | 71.01M | 96.86M | (48.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 189.2M | 115.98M | 4.58M | 55.83M | 505.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.66M) | 1.17M | (1.64M) | (2.43M) | (1.33M) |
| Financing Cash Flow | 232.91M | 117.14M | 2.94M | 53.39M | 503.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.12M | (62.1M) | (26.35M) | 50.59M | 312.29M |
| Free Cash Flow | (73.04M) | (93.61M) | (101.36M) | (99.89M) | (143.65M) |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.